Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: schadenfreude who wrote (4798)	11/20/1997 6:22:00 PM
From: chirodoc	Read Replies (1) \| Respond to of 17367

<<<<< Walker of Arris was one of them. Nice write-up. .............i didn't mean that i thought arris management was quesitonable. in fact i think their squna purchase is one of the new models going forward--a portent of things to come. .........thanks for the info from worth--and yes, i am adding to my arrs position.

To: schadenfreude who wrote (4798)	11/20/1997 7:15:00 PM
From: Andrew H	Respond to of 17367

OFF TOPIC >>It's interesting that you would bring up Arris in a discussion of questionable biotech managements. Worth magazine did an article a couple months ago on the six or so managers (in any industry) that best maximize shareholder value. Walker of Arris was one of them. Nice write-up.<< While stock price is not the only measure of shareholder value, it certainly is a primary one. I don't know anything about Walker, but if he has done such a fine job of maximizing shareholder value (compared to say other biotechs like AGPH or IDPH or IMNX, not to mention other industries), why is ARRS stock currently sitting on its 104 week lows? If that is maximizing shareholder value in the greatest bull market in history, then I worry about the credibility of the author.